Neuroendocrine cancer
Drug research and approvals for neuroendocrine cancer: what is recruiting, what Health Canada authorized, FDA orphan designations and EU medicines. See every condition.
As of Nov 22, 2026, 706 studies of neuroendocrine cancer are recruiting on ClinicalTrials.gov, and Health Canada has authorized 0 drug trials for it since 2013.
- Recruiting worldwide: 706
- Trials authorized in Canada: 0
- FDA orphan approvals: 0
- EU medicines: 0
- Application of 18F-SSTR2 Antagonist PET/CT in Neuroendocrine TumorsNCT07949396 · Not applicable · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Sep 3, 2026
- Application of 177Lu-SSTR2 Antagonist Therapy in Advanced Neuroendocrine TumorsNCT07949422 · Not applicable · Cancer Institute and Hospital, Chinese Academy of Medical Sciences · starts Nov 1, 2026
- Mechanical Characterization of Vestibular Schwannoma: Classification Based on Magnetic Resonance Elastography and Its…NCT07944833 · Not reported · Shengjing Hospital · starts Aug 10, 2026
- A Multicenter, Open-label, Phase 1/1b, Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Efficacy of…NCT07940881 · Phase 1 · SystImmune Inc. · starts Aug 24, 2026
- A Phase II Study of Nab-Paclitaxel Combined With Retlirafusp Alfa and Apatinib in Patients With Advanced Mucosal…NCT07934927 · Phase 2 · Sun Yat-sen University · starts Sep 29, 2026
- Adjuvant/Neoadjuvant Immunotherapy in Melanoma Based on Serial Plasma ctDNA MonitoringNCT07930182 · Phase 2 · H. Lee Moffitt Cancer Center and Research Institute · starts Oct 21, 2026
- Adrenal Diseases in the Population of Modena: A Clinical-Epidemiological Database of Patients Referred to the Adrenal…NCT07920198 · Not reported · Azienda Ospedaliero-Universitaria di Modena · starts Jul 9, 2026
- 68Ga-labeled Cholecystokinin Receptor (CCK2R) Targeted Molecular Probes in Early Tumor DiagnosisNCT07914764 · Not reported · Nanjing First Hospital, Nanjing Medical University · starts Aug 1, 2026
- High-precision Radiosurgery Followed by Minimally Invasive Surgical Approach in Patients With High-prominence Uveal…NCT07913412 · Not reported · University Hospital, Essen · starts Sep 1, 2019
Approved 5
- AvelumabMerkel cell cancer · Programmed cell death 1 ligand 1 other
- VandetanibMedullary cancer · Tyrosine-protein kinase SRC inhibitor
- RetifanlimabMerkel cell cancer · Programmed cell death protein 1 antagonist
- SelpercatinibMedullary cancer · Tyrosine-protein kinase receptor RET inhibitor
- PralsetinibMedullary cancer · Tyrosine-protein kinase receptor RET inhibitor
Phase 3 7
- PembrolizumabMerkel cell cancer · Programmed cell death protein 1 inhibitor
- FluorouracilThymidylate synthase inhibitor
- IrinotecanDNA topoisomerase I inhibitor
- Leucovorin
- CabozantinibMedullary cancer · Vascular endothelial growth factor receptor 2 inhibitor
- SurufatinibFibroblast growth factor receptor 1 inhibitor
- ToripalimabProgrammed cell death protein 1 antagonist
Phase 2 12 of 55
- CisplatinDNA inhibitor
- CarboplatinDNA inhibitor
- BevacizumabVascular endothelial growth factor A inhibitor
- NivolumabProgrammed cell death protein 1 inhibitor
- EverolimusFK506-binding protein 1A inhibitor
- PaclitaxelTubulin inhibitor
- CapecitabineThymidylate synthase inhibitor
- OxaliplatinDNA inhibitor
- TemozolomideDNA inhibitor
- IpilimumabCytotoxic T-lymphocyte protein 4 inhibitor
- SorafenibMedullary cancer · Serine/threonine-protein kinase RAF inhibitor
- OctreotideSomatostatin receptor agonist
Phase 1 or earlier 12 of 14
- FludarabineMedullary cancer
- TrastuzumabSomatostatinoma · Receptor protein-tyrosine kinase erbB-2 inhibitor
- AldesleukinMerkel cell cancer · Interleukin-2 receptor agonist
- RanitidineMedullary cancer · Histamine H2 receptor antagonist
- OmeprazoleMedullary cancer · Potassium-transporting ATPase inhibitor
- BortezomibMedullary cancer · 26S proteasome inhibitor
- Omega-3-ACID ethyl estersMerkel cell cancer
- SapanisertibMerkel cell cancer · Serine/threonine-protein kinase mTOR inhibitor
- SerplulimabProgrammed cell death protein 1 antagonist
- NavtemadlinMerkel cell cancer · Tumour suppressor p53/oncoprotein Mdm2 inhibitor
- GelatinMedullary cancer
- Interferon betaMerkel cell cancer
How its trials ended
262 ClinicalTrials.gov studies of the condition, classified by TrialPanorama, partly automatically, so some labels are wrongOf the 49 whose ending is known, 31% met their primary endpoint, 12% missed it and 57% stopped early.
- Ongoing11142%
- Completed, result not reported6926%
- Status unknown3313%
- Stopped: other or unclear176%
- Met its primary endpoint156%
- Missed its primary endpoint62%
- Stopped: enrollment or feasibility62%
- Stopped: sponsor or business decision31%
- Stopped: lack of efficacy1<1%
- Stopped: funding1<1%
Condition names come from Health Canada's trial database. Orphan designations and EU medicines are matched when their indication names the condition as whole words, so a broader or differently worded indication can be missed. Recruiting counts are live from ClinicalTrials.gov's own condition search, refreshed daily. ClinicalTrials.gov, Health Canada Clinical Trials Database, FDA orphan designations, EMA